Intech Investment Management LLC Buys 1,918 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Intech Investment Management LLC raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 12.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 17,309 shares of the company’s stock after purchasing an additional 1,918 shares during the quarter. Intech Investment Management LLC’s holdings in Tarsus Pharmaceuticals were worth $701,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of TARS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Tarsus Pharmaceuticals by 26.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock worth $66,000 after buying an additional 339 shares during the period. Quarry LP boosted its holdings in Tarsus Pharmaceuticals by 20.0% during the first quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after acquiring an additional 599 shares during the period. AlphaQuest LLC bought a new stake in Tarsus Pharmaceuticals during the first quarter valued at about $189,000. Allianz Asset Management GmbH acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $227,000. Finally, FORA Capital LLC bought a new position in shares of Tarsus Pharmaceuticals in the first quarter worth about $271,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 2.1%

Shares of TARS stock opened at $80.50 on Thursday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $83.47. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The stock has a fifty day moving average price of $68.45 and a 200 day moving average price of $53.77. The stock has a market cap of $3.42 billion, a P/E ratio of -39.85 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The company had revenue of $118.70 million during the quarter, compared to analysts’ expectations of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on TARS shares. Wall Street Zen upgraded Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright boosted their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, October 20th. Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Finally, Mizuho began coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $74.14.

Insider Activity

In related news, Director William J. Phd Link sold 27,116 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the transaction, the director owned 143,332 shares of the company’s stock, valued at $8,169,924. This represents a 15.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the transaction, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.97% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.